Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 2403435

Nonhuman primate bites.

D H Janda·D H Ringler·J K Hilliard·R C Hankin·F M Hankin
View original source ↗Export metadata ↓

Abstract

Nonhuman primate (monkey) bites to researchers and attending animal care staff may present problems in patient management. Such inoculations can transmit serious bacterial and viral infections to the human handlers. Significant local and systemic manifestations can subsequently develop following such an injury. Since Herpesvirus simiae (B virus) is enzootic in Asiatic monkeys of the genus Macaca, and since B virus infection in humans is usually fatal, additional prophylactic and therapeutic measures must be taken when persons are bitten by macaque monkeys. Primate bites require early aggressive intervention.

Explore related subjects

AcyclovirAdultAnimalsBacteroides InfectionsBites and StingsCephalosporinsEikenella corrodensHumansMacacaMacaca mulattaMaleStaphylococcal InfectionsCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D H Janda, D H Ringler, J K Hilliard, R C Hankin, F M Hankin. 1990. Nonhuman primate bites.. https://doi.org/10.1002/jor.1100080119

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography.

We are developing assays for noninvasive, quantitative imaging of reporter genes with positron emission tomography (PET), for application both in animal models and in human gene therapy. We report here a method to improve the detection of lower levels of PET reporter gene expression by utilizing a mutant herpes simplex virus type 1 thymidine kinase (HSV1-sr39tk) as a PET reporter gene. The HSV1-sr39tk mutant was identified from a library of site-directed mutants. Accumulation (net uptake) of the radioactively labeled substrates [8-(3)H]penciclovir ([8-(3)H]PCV), and 8-[(18)F]fluoropenciclovir (FPCV) in C6 rat glioma cells expressing HSV1-sr39tk is increased by a factor of approximately 2.0 when compared with C6 cells expressing wild-type HSV1-tk. The increased imaging sensitivity of HSV1-sr39tk when FPCV is used is also demonstrated in vivo both with tumor cells stably transfected with either HSV1-tk or HSV1-sr39tk, and after hepatic delivery of HSV1-tk or HSV1-sr39tk by using adenoviral vectors. The use of HSV1-sr39tk as a PET reporter gene and FPCV as a PET reporter probe results in significantly enhanced sensitivity for imaging reporter gene expression in vivo.

Acyclovir↗
PubMed2000

Alteration in the radiation-induced LD release in HeLa cells by acyclovir.

The aim of the present investigation was to study the effect of various concentrations of acyclovir (ACV) alone or the effect of 0.1 micromol/l acycloir pretreatment on the radion-induced lactate dehydrogenase (LD) release by HeLa cells exposed to 0-3 Gy of gamma-radiation. The plateau-phase cells were treated with 0-100 micromol/l ACV for 8 h or 0.1 micromol/l ACV before exposure to 0-3 Gy of gamma-radiation. The whole media was removed from the culture and the LD release was measured at 0, 0.5, 1, 2, and 4 h post-drug treatment or post-irradiation. The ACV treatment resulted in a concentration-dependent elevation in the LD release at all the post-treatment time periods. A peak level for LD release was observed at 0 h up to 1 micromol/l ACV and declined thereafter. However, at higher doses a highest elevation in LD release was observed at 1 h post-treatment. Pretreatment of HeLa cells with 0.1 micromol/l ACV before irradiation to different doses of gamma-radiation resulted in significant elevation in the release of LD in the medium. The LD release was twofold greater in the ACV+irradiation group at 0 h post-irridiation when compared with the concurrent PBS+gamma-radiation group. The highest increase in LD activity was observed at 0 h post-irradiation and a gradual decline thereafter, without restoration to non-drug treated control level up to 4 h post-irradiation. The LD measurements can serve as a short-term assay to evaluate the cytotoxicity of ACV or radiation in vitro.

Acyclovir↗
PubMed2000

Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: a randomized, double-blind, placebo-controlled trial. Penciclovir Cream Herpes Labialis Study Group.

OBJECTIVE: The purpose of this study was to further define the therapeutic value of penciclovir cream in the treatment of sunlight-induced herpes labialis by comparing its efficacy and tolerability with those of an inactive control (purified water). METHODS: In this randomized, double-blind, placebo-controlled, parallel-group clinical trial, lesions were induced by exposure to sunlight. Treatment was self-initiated within 1 hour of development of the signs or symptoms of a recurrence. RESULTS: Healthy male and female patients (mean age, 38.3 years; range, 18 to 81 years) who had a history of sunlight-induced herpes labialis (mean of 6 recurrences in previous 12 months) applied either penciclovir cream (n = 266) or purified water (n = 275). Penciclovir cream significantly decreased the time to lesion healing (P < 0.001), with a reduction in median time of up to 2 days. The efficacy of penciclovir cream was further supported by a significant reduction in maximum lesion area (P = 0.008), a faster loss of lesion-associated symptoms (P = 0.026), and significant reductions in daily assessments of pain (P < or = 0.040), itching (P < or = 0.032), burning (P < or = 0.028), and tenderness (P < or = 0.026) as moderate or severe. These effects were reinforced by the results of the daily self-assessment of lesion attributes, with significantly fewer severe/extreme assessments of lesion size (P < or = 0.003), noticeability (P < or = 0.003), amount of scab/crust (P < or = 0.003), raised/ swollen area (P < or = 0.040), soreness/tenderness (P < or = 0.043), and overall severity (P < or = 0.001) throughout the study period. CONCLUSIONS: Penciclovir cream has demonstrated efficacy for a broad range of clinically important outcomes. Significant effects on lesion area, lesion symptoms, and other lesion attributes extend the clinical efficacy of penciclovir cream beyond lesion healing.

Acyclovir↗